middle.news
Invex Builds a Second Neurology Pipeline With Rekover Acquisition
9:42am on Monday 26th of October, 2026 AEDT
•
Biotechnology
Read Story
Invex Builds a Second Neurology Pipeline With Rekover Acquisition
9:42am on Monday 26th of October, 2026 AEDT
Key Points
Acquisition of Rekover for 45 million shares and 91.25 million performance rights
REVIVE Phase 2a trial planned for chronic optic neuropathy in multiple sclerosis
$10 million placement priced at $0.08 a share
Pro forma shares increase from 75.2 million to 245.2 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invex Therapeutics (ASX:IXC)
OPEN ARTICLE